[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)]
[Notices]
[Page 10025]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02673]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Inhibition of
Plasmodial Surface Anion Channels for the Treatment or Prevention of
Malaria
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive
Commercialization Patent License to practice the inventions embodied in
the Patents and Patent Applications listed in the Summary Information
section of this notice to Microbiotix, Inc. (``Microbiotix'') located
in Worcester, Massachusetts.
DATES: Only written comments and/or applications for a license which
are received by the National Institute of Allergy and Infectious
Diseases' Technology Transfer and Intellectual Property Office on or
before February 24, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Commercialization
Patent License should be directed to: Peter Tung, Technology Transfer
and Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804 Telephone:
(301) 496-2644; Facsimile: (240) 627-3117; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 61/083,000, filed
July 23, 2008 and entitled ``Inhibitors of the Plasmodial Surface Anion
Channel as Antimalarials'' [HHS Reference No. E-202-2008/0-US-01]; PCT
Patent Application PCT/US09/50637, filed July 15, 2009 and entitled
``Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials''
[HHS Reference No. E-202-2008/0-PCT-02]; and U.S. and foreign patent
applications claiming priority to the aforementioned applications.
United States Provisional Patent Application No. 61/474,583, filed
April 12, 2011 and entitled ``Plasmodial Surface Anion Channel
Inhibitors for the Treatment of Malaria'' [HHS Reference No. E-145-
2011/0-US-01]; PCT Patent Application PCT/US12/33072, filed April 11,
2012 and entitled ``Plasmodial Surface Anion Channel Inhibitors for the
Treatment of Malaria'' [HHS Reference No. E-202-2008/0-PCT-02]; and
U.S. and foreign patent applications claiming priority to the
aforementioned applications.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: ``Methods of preventing and/or
treating malaria infection by inhibition of Plasmodium Surface Anion
Channels (PSAC) with anti-PSAC compounds.''
This technology discloses a novel anion channel on the surface of
red blood cells (RBCs) in animals infected with Plasmodium. Named PSAC
for ``plasmodium surface anion channel,'' this channel protein
facilitates the transport of nutrients into RBCs for the plasmodium
parasite. Sugars, amino acids, purines, vitamins, and precursors for
phospholipid biosynthesis have markedly increased uptake into infected
RBCs via PSAC. Many of these nutrients have negligible uptake in
uninfected RBCs. PSACs, which allow nutrients to reach the growing
plasmodium parasites inside RBCs, therefore serves as a new target for
the development of antimalarial compounds. The disclosed anti-PSAC
compositions and methods of using these anti-PSAC compounds provide a
means for prevention or treatment of malaria infection by blocking
nutrients to plasmodium parasites.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Institute of Allergy and Infectious Diseases receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Commercialization Patent
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-02673 Filed 2-8-17; 8:45 am]
BILLING CODE 4140-01-P